2016 ASCO Annual Meeting Abstract 8007: Phase 1/2 Study of Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM): A Multiple Myeloma Research Consortium Multicenter Study
KPd is well tolerated and highly active (≥PR 84%) with encouraging PFS (median 12.9 mo) in less pretreated, mostly LEN-refractory and PI-naive/sensitive RRMM in the era of increased use of extended LEN treatment.
ASCO
In The News
American Society of Hematology 2016 Annual Meeting
Session 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation in Myeloma I
American Society of Hematology 2016 Annual Meeting
Session 653. Myeloma: Therapy, excluding Transplantation: IMiD/Proteasome Inhibitor Combinations and Maintenance Therapy
American Society of Hematology 2016 Annual Meeting
Abstract 1143: Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study
American Society of Hematology 2016 Annual Meeting
Abstract 673: Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)
In The Literature
Bone Marrow Transplant